CristinaGasparettoMD

Oncology • Durham, NC

Associate Professor, Medicine, Duke University School of Medicine

Join to view full profile

Dr. Gasparetto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gasparetto's full profile

Already have an account?

Office
2100 Erwin Rd
Durham, NC 27705
Phone+1 919-620-4467

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Sapienza University of RomeClass of 1986

Certifications & Licensure

NC State Medical License 1997 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2008 Jul 01
Terminated
Phase 1
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy Start of enrollment: 2008 Aug 01
Completed
Phase 2
Bortezomib With Melphalan and Prednisone for Multiple Myeloma Start of enrollment: 2004 Jul 01
Completed
Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT Start of enrollment: 2011 Feb 01
Terminated
Phase 1
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma Start of enrollment: 2013 Jan 01
Completed
Phase 1
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Unknown status
Phase 1, Phase 2
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Start of enrollment: 2013 Mar 01
Terminated
Phase 1
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma Start of enrollment: 2013 Jan 07
Active, not recruiting
Phase 1, Phase 2
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Start of enrollment: 2015 Jul 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

173 citations
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson
The Lancet. Haematology. 2019-07-18
237 citations
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson, Robert L. Schlossman, Melissa Alsina, Donna M. Weber, Steven Coutre
Blood. 2013-10-03
46 citations
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios A. Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo
Blood. 2021-03-04

Journal Articles

Selinexor plus Low-Dose Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Suzanne Lentzsch, Cristina Gasparetto, Blood

Abstracts/Posters

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect¬ MM R...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory ...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelate...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.
2019 ASCO Annual Meeting - 6/1/2019
Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to Be Presented at the American Society of Hematology 2020 Annual MeetingNovember 4th, 2020
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
Expert Highlights Early Promise of Selinexor in MyelomaFebruary 8th, 2018